EE140 Estimated Costs for All-Cause Grade 3/4 Adverse Events Among First-Line Tyrosine Kinase Inhibitor Plus Immuno-Oncology-Based Combination Therapies for Patients with Advanced Renal Cell Carcinoma from the United States Perspective

Abstract

Three tyrosine kinase inhibitor + immuno-oncology (TKI+IO) regimens (i.e., cabozantinib+nivolumab [C+N], axitinib+pembrolizumab [A+P], and lenvatinib+pembrolizumab [L+P]) have been approved by the Food and Drug Administration (FDA) for the first-line treatment of advanced renal cell carcinoma (aRCC). Given the limited information on costs of treating adverse events (AEs), we estimated the costs of all-cause grade 3/4 AEs for C+N, A+P, and L+P from the CheckMate 9ER, KEYNOTE-426, and CLEAR trials, respectively.